Release date: 2015-09-29 Pancreatic cancer is called "the king of cancer" because of its difficult diagnosis, poor prognosis and high mortality. The ratio of morbidity to mortality is 1:0.99. At present, the surgical rate of pancreatic cancer is extremely low, the effect of radiotherapy and chemotherapy is not good, and the prognosis of comprehensive treatment is not ideal. With the development of the translational medicine model, some new treatment methods have gradually been discovered. Gene therapy Cancer genome mapping analysis found that a subpopulation of pancreatic cancer has a very strong angiogenic gene tag, which can promote the growth of pancreatic cancer cells; the clinical application of E47 gene is expected; K-ras gene mutation can induce the expression of ICAM-1, Thereby producing pancreatic precancerous lesions; blocking neutralizing antibodies against ICAM-1 can block pancreatic precancerous lesions; ATDC gene can be used as a potential effective target for the treatment of pancreatic cancer. In addition, gene combination therapy has potential application value, and oncolytic vaccinia virus can effectively treat pancreatic cancer, but some methods need further verification. Nanocarrier The novel multi-layered phospholipid-polymer hybrid nanocarriers can carry out three active ingredients in the FOLFIRINOX chemotherapy regimen, increase the half-life of the drug in vivo, increase tumor targeting by nearly 10 times, and reduce normal tissue. Damage. Chemotherapy Rapamycin brings new therapeutic hopes to individuals who are at risk of carrying a mutated PTEN gene. In the United States in 2013, Canada in 2014, and 2015 in the European Union, Abraxane (albumin-bound paclitaxel) was combined with gemcitabine for first-line treatment of adult patients with metastatic pancreatic cancer. The efficacy of the drug Sabutoclax in combination with antibiotics minocycline, gemcitabine combined with linoleic acid, doxorubicin and PI3K inhibitor BEZ235 was confirmed by experiments. Olapani can increase the efficacy of gemcitabine. Heparan sulfate analogs significantly reduce anticoagulant activity while retaining relevant anti-tumor properties. immunity therapy Clinical studies found an average overall survival of 6.1 months in the GVAX Pancreas+ CRS-207 combination vaccine group compared with a mean overall survival of 3.9 months in the GVAX Pancreas vaccine group. Transfection of dendritic cells with MUC1 mRNA DCs induces specific anti-pancreatic cancer CTLs and better kills cancer cells. Mutation of K-ras gene in pancreatic cancer can trigger the expression of GM-CSF protein, and GM-CSF blocking pancreatic cancer cells has immunotherapy. traditional Chinese medicine Tripterygium wilfordii extract triptolide can induce chronic cell endoplasmic reticulum stress pathway to inhibit GRP78, which protects cancer cells, and ultimately leads to pancreatic cancer cell death. Extracellular matrix Elimination of galectin-1 inhibits proliferation and reduces angiogenesis; drugs that silence CCN1 slow or even stop the growth of pancreatic cancer tumors. After elevated levels of fascin in patients with pancreatic cancer, cancer recurrence is more likely to occur and tends to die more quickly. Inhibition of the expression of this protein has potential therapeutic implications. Radiation Therapy Three-dimensional intensity-modulated radiotherapy can better increase the local radiation dose, reduce the dose of radiation-sensitive tissue around the tumor, and obtain better local control rate and lower radiation damage. Stereotactic radiotherapy (SBRT) was used in clinical practice to find that the median survival time of pancreatic cancer was 12.5 months. The clinical application analysis of the cyberknife showed that the median survival time of the patients was 12.5 months, the 1-year survival rate was 53.9%, and the 2-year survival rate was 35.1%. Synchronous three-dimensional conformal radiotherapy based on gemcitabine or fluorouracil increased the median survival of pancreatic cancer patients from 8 months to 13 months in the chemotherapy alone group, and the 1-year survival rate increased from 14.3% to 51.4%. In addition, photodynamic therapy has certain application prospects. Precision medicine The promotion of precision medicine in pancreatic cancer requires more basic and experimental data, but the new model of precision medicine has a guiding role in the treatment of pancreatic cancer. In short, the translational medicine model is developing in the direction of individualization, combination and precision in the treatment of pancreatic cancer, which provides new hope for patients with pancreatic cancer. Author: General Hospital of Shenyang Military Region, Liu Xu Zhong Guo Source: China Medical Information Guide We, Jiangsu YanFang Medical Technology Co., Ltd, commenced our medical gloves manufacturing in 2020. Currently, we possess a total of 12 high-capacity NBR Glove Dipping Production Lines. Industrial Nitrile Gloves,Nitrile Gloves Extra Large,Nitrile Powder Free Glove,Nitrile Powder Disposable Examination Gloves Jiangsu Yanfang Medical Technology Co.,Ltd. , https://www.yanfangchina.com
Likewise, we are not only certified with ISO9001, ISO13485 but also fully complied with the essential USFDA, CE Compliances, as well as obtaining relevant accreditation of FDA510K, EN455, and EN374.
Nonetheless, our NBR Examination, Chemotherapy, and Food Grade products are being well established in both US and Europe markets.
We look forward to cooperating and working closely with our valuable customers and stakeholders, who are seeking long-term business relationships in high-quality NBR glove supplies.
Progress in translational medicine for the treatment of pancreatic cancer: from Chinese medicine to precision medicine